Neuroimaging research suggests that atrophy in the hypothalamus, marked by a decrease in volume, is linked to AD pathology (Aβ42, tau, and phosphorylated tau) and signals structural damage in this vital brain area, underscoring its significance in the disease’s progression [9, 10]. This evidence concerns the gene MAPT and Alzheimer disease.